Gastroenterology
Volume 137, Issue 6 , Pages 2146-2157 , December 2009

Differential Importance of Glucose-Dependent Insulinotropic Polypeptide vs Glucagon-Like Peptide 1 Receptor Signaling for Beta Cell Survival in Mice

  • Adriano Maida

      Affiliations

    • Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Tanya Hansotia

      Affiliations

    • Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Christine Longuet

      Affiliations

    • Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Yutaka Seino

      Affiliations

    • Kyoto University Graduate School of Medicine, Kyoto, Japan
    • ,
  • Daniel J. Drucker

      Affiliations

    • Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationReprint requests Address requests for reprints to: Daniel J. Drucker, MD, Mount Sinai Hospital, Samuel Lunenfeld Research Institute, 60 Murray Street, Mailbox 39, Toronto, Ontario, Canada M5T 3L9. fax: (416) 361-2669

Received 18 June 2009 ,Accepted 2 September 2009.

References 

  1. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest. 2007;117:24–32
  2. Mayo KE, Miller LJ, Bataille D, et al. International Union of Pharmacology (XXXV. The glucagon receptor family). Pharmacol Rev. 2003;55:167–194
  3. Hansotia T, Maida A, Flock G, et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest. 2007;117:143–152
  4. Kim SJ, Nian C, McIntosh CH. Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J Biol Chem. 2007;282:34139–34147
  5. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002;8:738–742
  6. McClean PL, Irwin N, Cassidy RS, et al. GIP receptor antagonism reverses obesity, insulin resistance and associated metabolic disturbances induced in mice by prolonged consumption of high fat diet. Am J Physiol Endocrinol Metab. 2007;293:E1746–E1755
  7. Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes. 2004;53:2181–2189
  8. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–165
  9. Holz GGt, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature. 1993;361:362–365
  10. Stoffers DA, Kieffer TJ, Hussain MA, et al. Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase b-cell mass in mouse pancreas. Diabetes. 2000;49:741–748
  11. Xu G, Stoffers DA, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270–2276
  12. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002;143:4397–4408
  13. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144:5149–5158
  14. Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia. 2002;45:1263–1273
  15. Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem. 2003;278:471–478
  16. Ling Z, Wu D, Zambre Y, et al. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch. 2001;438:382–387
  17. Trumper A, Trumper K, Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J Endocrinol. 2002;174:233–246
  18. Trumper A, Trumper K, Trusheim H, et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol. 2001;15:1559–1570
  19. Kim SJ, Winter K, Nian C, et al. GIP stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3-K)/ protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1 and downregulation of bax expression. J Biol Chem. 2005;280:22297–22307
  20. Pamir N, Lynn FC, Buchan AM, et al. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. Am J Physiol Endocrinol Metab. 2003;284:E931–E939
  21. Hansotia T, Baggio LL, Delmeire D, et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes. 2004;53:1326–1335
  22. Lamont BJ, Drucker DJ. Differential anti-diabetic efficacy of incretin agonists vs (DPP-4 inhibition in high fat fed mice). Diabetes. 2008;57:190–198
  23. Maida A, Lovshin JA, Baggio LL, et al. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances {beta}-cell function but does not inhibit gastric emptying in mice. Endocrinology. 2008;149:5670–5678
  24. Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003;46:2774–2789
  25. Hinke SA, Gelling RW, Pederson RA, et al. Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes. 2002;51:652–661
  26. Kuhn-Wache K, Manhart S, Hoffmann T, et al. Analogs of glucose-dependent insulinotropic polypeptide with increased dipeptidyl peptidase IV resistance. Adv Exp Med Biol. 2000;477:187–195
  27. Pieper AA, Brat DJ, Krug DK, et al. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc Natl Acad Sci U S A. 1999;96:3059–3064
  28. Rhodes CJ. Type 2 diabetes—a matter of beta-cell life and death?. Science. 2005;307:380–384
  29. Vilsboll T, Krarup T, Madsbad S, et al. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia. 2002;45:1111–1119
  30. Vilsboll T, Knop FK, Krarup T, et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab. 2003;88:4897–4903
  31. Rankin MM, Kushner JA. Adaptive beta cell proliferation is severely restricted with advanced age. Diabetes. 2009;58:1365–1372
  32. Tschen SI, Dhawan S, Gurlo T, et al. Age-dependent decline in beta cell proliferation restricts the capacity of beta cell regeneration in mice. Diabetes. 2009;58:1312–1320
  33. Kim SJ, Nian C, Widenmaier S, et al. Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Mol Cell Biol. 2008;28:1644–1656
  34. Ehses JA, Casilla VR, Doty T, et al. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology. 2003;144:4433–4445
  35. Pederson RA, Satkunarajah M, McIntosh CH, et al. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor −/− mice. Diabetes. 1998;47:1046–1052
  36. Buteau J, Foisy S, Joly E, et al. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes. 2003;52:124–132
  37. MacDonald PE, Wang X, Xia F, et al. Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways. J Biol Chem. 2003;278:52446–52453
  38. Park S, Dong X, Fisher TL, et al. Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J Biol Chem. 2006;281:1159–1168
  39. Brubaker PL, Drucker DJ. Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut and central nervous system. Endocrinology. 2004;145:2653–2659
  40. Ahren B, Winzell MS, Wierup N, et al. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide. Regul Pept. 2007;143:97–103
  41. Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55:1695–1704
  42. Flock G, Baggio LL, Longuet C, et al. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes. 2007;56:3006–3013
  43. Kim SJ, Nian C, Doudet DJ, et al. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes. 2008;57:1331–1339
  44. Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003;52:741–750

 View this article's video abstract at www.gastrojournal.org.

 Conflicts of interest The authors disclose the following: Dr Drucker has served as an advisor or consultant within the past 12 months to Amylin Pharmaceuticals, Arena Pharmaceuticals Inc, Arisaph Pharmaceuticals Inc, Eli Lilly and Company, GlaxoSmithKline, Glenmark Pharmaceuticals, Hoffman-LaRoche Inc, Isis Pharmaceuticals Inc, Merck Research Laboratories, Metabolex Inc, Novartis Pharmaceuticals, Novo Nordisk Inc, Phenomix Inc, and Transition Pharmaceuticals Inc. Neither Dr Drucker nor his family members hold stock directly or indirectly in any of these companies. The remaining authors disclose no conflicts.

 Funding A.M. was supported by funding from a Canadian Diabetes Association Doctoral Research Award and a Canadian Institutes of Health Research graduate scholarship. These studies were supported in part by a grant from the Juvenile Diabetes Research Foundation (JDRF #1-2006-796) and from the Canadian Institutes of Health Research MOP 82700. D.J.D. was supported in part by the Canada Research Chairs Program.

PII: S0016-5085(09)01569-8

doi: 10.1053/j.gastro.2009.09.004

Gastroenterology
Volume 137, Issue 6 , Pages 2146-2157 , December 2009

Article Tools

* Image Usage & Resolution